This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Iervasi, G. Articles by Donato, L. Search for Related Content PubMed PubMed Citation Articles by Iervasi, G. Articles by Donato, L.

Atrial Natriuretic Peptide Is Not Degraded by the Lungs in Humans

Laboratory of Cardiovascular Endocrinology, Consiglio Nazionale delle Ricerche Institute of Clinical Physiology, Pisa, Italy

Address all correspondence and requests for reprints to: Giorgio Iervasi, Consiglio Nazionale delle Ricerche Institute of Clinical Physiology, Via Savi 8, 56100 Pisa, Italy. E-mail:iervasi{at}nsifc.ifc.pi.cnr.it

In an attempt to identify and quantify the sites of atrial natriuretic peptide (ANP) degradation, particularly the lungs, a new tracer method to study ANP metabolism in vivo in humans was developed and applied to patients with left ventricular dysfunction. Thirteen male, normotensive, cardiac patients with different degrees of left ventricular myocardial involvement were enrolled in the study. The study protocol required constant infusion (3 patients) or bolus injection (10 patients) of ¹²⁵I-labeled ANP just upstream of the right atrium and blood sampling from different sites (pulmonary artery, aorta, inferior vena cava, and femoral vein) during the hemodynamic study. Data analysis was based on a kinetic model consisting of three blocks in series (right heart, lungs and left heart, and periphery) supplied by the same plasma flow (plasma cardiac output). Plasma levels of native ANP were measured with a sensitive and specific immunoradiometric assay method. ANP values measured in the aorta (163.9 ± 144.8 pg/mL, n = 80) were superimposable on those measured in the pulmonary artery (161.8 ± 136.5 pg/mL, n = 80). Negligible extraction of ¹²⁵I-labeled ANP was found in the lungs and left heart block (on average 0.08 ± 3.92%), whereas the peripheral block extraction (46.2 ± 7.8%) accounted for almost total hormone removal from the blood (whole body extraction was 46.4 ± 6.6%). ANP metabolic clearance rate (3.11 ± 1.48, range 1.4–6.8 L/min) declined with the progression of left ventricular dysfunction (plasma cardiac output 3.46 ± 1.08, range 1.2–5.7 L/min), and a close correlation between metabolic clearance rate and cardiac output was evident. Our data suggest that lungs do not extract, or extract only very small amounts, of labeled ANP administered iv to patients with different degrees of left ventricular myocardial involvement, and whole body extraction of labeled ANP remains relatively stable with the progression of disease, and the large reductions in clearance values observed in our patients can be ascribed mainly to the reductions in cardiac output.